Héctor Ortega

12.1k total citations · 4 hit papers
117 papers, 8.6k citations indexed

About

Héctor Ortega is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Héctor Ortega has authored 117 papers receiving a total of 8.6k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Physiology, 64 papers in Pulmonary and Respiratory Medicine and 29 papers in Surgery. Recurrent topics in Héctor Ortega's work include Asthma and respiratory diseases (81 papers), Respiratory and Cough-Related Research (50 papers) and Eosinophilic Esophagitis (29 papers). Héctor Ortega is often cited by papers focused on Asthma and respiratory diseases (81 papers), Respiratory and Cough-Related Research (50 papers) and Eosinophilic Esophagitis (29 papers). Héctor Ortega collaborates with scholars based in United States, United Kingdom and Canada. Héctor Ortega's co-authors include Oliver N. Keene, Ian Pavord, Steven W. Yancey, Pascal Chanez, Eugene R. Bleecker, Peter Howarth, Roland Buhl, Stephanie Korn, Lynn E. Katz and Charlene M. Prazma and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Héctor Ortega

103 papers receiving 8.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

2014 1.6k citations Héctor Ortega, Ian Pavord et al. New England Journal of Medicine profile →
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

2012 1.6k citations Ian Pavord, Eugene R. Bleecker et al. profile →
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

2014 1.2k citations Philip J. Thompson, Oliver N. Keene et al. New England Journal of Medicine profile →
Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies

2016 396 citations Héctor Ortega, Steven W. Yancey et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Héctor Ortega	7.1k	5.4k	2.0k	1.8k	1.5k	117	8.6k
Andrew Menzies‐Gow	6.6k 0.9×	4.5k 0.8×	1.4k 0.7×	1.8k 1.0×	1.7k 1.1×	189	7.9k
Steven W. Yancey	7.0k 1.0×	5.7k 1.1×	1.3k 0.7×	1.2k 0.7×	1.3k 0.9×	122	8.2k
Stephanie Korn	5.5k 0.8×	4.3k 0.8×	1.1k 0.6×	1.4k 0.8×	1.4k 0.9×	133	6.5k
Jonathan Corren	9.0k 1.3×	5.2k 1.0×	1.4k 0.7×	2.6k 1.4×	4.6k 3.0×	225	11.0k
Ruth H. Green	5.5k 0.8×	4.2k 0.8×	808 0.4×	1.6k 0.9×	958 0.6×	32	6.5k
Jorge Máspero	3.9k 0.5×	2.4k 0.4×	805 0.4×	1.1k 0.6×	1.6k 1.0×	136	4.7k
Roland Buhl	4.3k 0.6×	3.6k 0.7×	680 0.3×	1.0k 0.6×	1.0k 0.7×	148	5.5k
Márcia Margaret Menezes Pizzichini	4.0k 0.6×	3.6k 0.7×	554 0.3×	692 0.4×	675 0.4×	71	5.0k
Stephen C. Lazarus	3.5k 0.5×	3.1k 0.6×	330 0.2×	1.1k 0.6×	675 0.4×	108	5.3k
Njira Lugogo	2.5k 0.3×	2.1k 0.4×	469 0.2×	735 0.4×	458 0.3×	160	3.9k

Countries citing papers authored by Héctor Ortega

Since Specialization

Citations

This map shows the geographic impact of Héctor Ortega's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Héctor Ortega with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Héctor Ortega more than expected).

Fields of papers citing papers by Héctor Ortega

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Héctor Ortega. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Héctor Ortega. The network helps show where Héctor Ortega may publish in the future.

Co-authorship network of co-authors of Héctor Ortega

This figure shows the co-authorship network connecting the top 25 collaborators of Héctor Ortega. A scholar is included among the top collaborators of Héctor Ortega based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Héctor Ortega. Héctor Ortega is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ortega, Héctor, et al.. (2025). In-vitro Characterization of Solrikitug, A Differentiated Anti-TSLP Antibody, Provides Distinct Epitope Binding Profile and Superior Potency Compared to Tezepelumab. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A1393–A1393. 1 indexed citations

Ortega, Héctor, et al.. (2025). Chelation-Based Electrochemical Sensor for Histamine Detection. Journal of The Electrochemical Society. 172(10). 107502–107502.

Ortega, Héctor, et al.. (2024). S635 Role of TSLP in an Experimental Mouse Model of Eosinophilic Esophagitis. The American Journal of Gastroenterology. 119(10S). S439–S439.

Ortega, Héctor, et al.. (2020). Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs. SHILAP Revista de lepidopterología. 1 indexed citations

Llanos, Jean‐Pierre, Héctor Ortega, Michael Bogart, et al.. (2020). <p>Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs</p>. Journal of Asthma and Allergy. Volume 13. 77–87. 44 indexed citations

Condreay, Lynn D., Mathias Chiano, Héctor Ortega, et al.. (2017). No genetic association detected with mepolizumab efficacy in severe asthma. Respiratory Medicine. 132. 178–180. 14 indexed citations

Nelsen, Linda, Miriam Kimel, Lindsey Murray, et al.. (2017). Qualitative evaluation of the St George's Respiratory Questionnaire in patients with severe asthma. Respiratory Medicine. 126. 32–38. 23 indexed citations

Nelsen, Linda, Margaret Vernon, Héctor Ortega, et al.. (2017). Evaluation of the psychometric properties of the St George's Respiratory Questionnaire in patients with severe asthma. Respiratory Medicine. 128. 42–49. 8 indexed citations

Ortega, Héctor, et al.. (2015). Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma (vol 371, pg 1198, 2014). New England Journal of Medicine. 372. 1777–1777. 3 indexed citations

10.

Ortega, Héctor, Mark Liu, Ian Pavord, et al.. (2014). Late-breaking abstract: Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal. 44(Suppl 58). 2906–2906. 1 indexed citations

11.

Ortega, Héctor, Hao Li, Robert Suruki, et al.. (2014). Cluster Analysis and Characterization of Response to Mepolizumab. A Step Closer to Personalized Medicine for Patients with Severe Asthma. Annals of the American Thoracic Society. 11(7). 1011–1017. 89 indexed citations

12.

Katz, Lynn E., Gerald J. Gleich, Benjamin Hartley, Steven W. Yancey, & Héctor Ortega. (2014). Blood Eosinophil Count Is a Useful Biomarker to Identify Patients with Severe Eosinophilic Asthma. Annals of the American Thoracic Society. 11(4). 531–536. 161 indexed citations

13.

Ortega, Héctor, Lynn E. Katz, Benjamin Hartley, & Steve Yancey. (2013). Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. European Respiratory Journal. 42(Suppl 57). P855–P855. 1 indexed citations

14.

Klion, Amy D., Florence Roufosse, Jean‐Emmanuel Kahn, et al.. (2012). Long-term Safety And Efficacy Of Mepolizumab For The Treatment Of Hypereosinophilic Syndrome. Journal of Allergy and Clinical Immunology. 129(2). AB203–AB203. 1 indexed citations

15.

Edin, Heather M., et al.. (2009). Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life. Annals of Allergy Asthma & Immunology. 102(4). 323–327. 3 indexed citations

16.

Renzi, Paolo, Lisa A. Howard, Héctor Ortega, Faiz Ahmad, & Kenneth R. Chapman. (2009). Low-dose fluticasone propionate with and without salmeterol in steroid-naïve patients with mild, uncontrolled asthma. Respiratory Medicine. 104(4). 510–517. 19 indexed citations

17.

Bleecker, Eugene R., Harold S. Nelson, Monica Kraft, et al.. (2009). β2-Receptor Polymorphisms in Patients Receiving Salmeterol with or without Fluticasone Propionate. American Journal of Respiratory and Critical Care Medicine. 181(7). 676–687. 81 indexed citations

18.

Fink, Jordan N., Héctor Ortega, Herbert Y. Reynolds, et al.. (2005). Needs and Opportunities for Research in Hypersensitivity Pneumonitis. American Journal of Respiratory and Critical Care Medicine. 171(7). 792–798. 129 indexed citations

19.

Banks‐Schlegel, Susan, et al.. (2004). Future Research Directions in Asthma. American Journal of Respiratory and Critical Care Medicine. 170(6). 683–690. 52 indexed citations

20.

Ortega, Héctor, et al.. (1998). Evaluación de un programa de rehabilitación del paciente esquizofrénico. 41(2). 51–59. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact